Pretreatment with troglitazone decreases lethality during endotoxemia in mice

Karen Reynolds, Bo Novosad, Adam Hoffhines, Jenny Gipson, Jared Johnson, Jeffrey Maurice Peters, Frank Gonzalez, Jeffrey Gimble, Molly Hill

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Troglitazone is an oral antidiabetic drug that is a ligand for peroxisome proliferator activated receptor γ (PPARγ). Based on other studies that have implicated an immunosuppressive role for PPARγ during inflammatory responses, we hypothesized that troglitazone treatment would improve survival in a murine model of endotoxemia and that the protective effect would be mediated by decreased expression of inflammatory mediators. C57B1/6N x Sv/129 (wild-type [WT]) or PPARα null mice treated for 2 weeks with dietary troglitazone (0.1%) had significantly fewer deaths and a higher LD50 value compared to control-fed mice when challenged with lipopolysaccharide (LPS). PPARα null mice were more sensitive to the lethal effects of LPS as evidenced by a 2-fold lower LD50 (6.6 mg/kg) compared to WT mice (14.6 mg/kg). Troglitazone treatment had no significant effect on LPS-induced plasma TNF, glucose, or nitric oxide levels in WT or PPARα null mice at any of the time points examined. However, troglitazone treatment significantly reduced LPS-induced plasma IL-6 levels in both WT and PPARα null mice. The results of these studies suggest that troglitazone treatment protects mice against a lethal challenge of LPS, but whether or not this effect is mediated through decreased expression of inflammatory mediators remains unclear.

Original languageEnglish (US)
Pages (from-to)307-314
Number of pages8
JournalJournal of Endotoxin Research
Volume8
Issue number4
DOIs
StatePublished - Jan 1 2002

Fingerprint

troglitazone
Endotoxemia
Peroxisome Proliferator-Activated Receptors
Lipopolysaccharides
Lethal Dose 50
Immunosuppressive Agents
Hypoglycemic Agents
Interleukin-6
Nitric Oxide

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Molecular Biology
  • Cell Biology
  • Infectious Diseases

Cite this

Reynolds, Karen ; Novosad, Bo ; Hoffhines, Adam ; Gipson, Jenny ; Johnson, Jared ; Peters, Jeffrey Maurice ; Gonzalez, Frank ; Gimble, Jeffrey ; Hill, Molly. / Pretreatment with troglitazone decreases lethality during endotoxemia in mice. In: Journal of Endotoxin Research. 2002 ; Vol. 8, No. 4. pp. 307-314.
@article{8cc2bc6a17674ea9bb6b3f07ab59c0d0,
title = "Pretreatment with troglitazone decreases lethality during endotoxemia in mice",
abstract = "Troglitazone is an oral antidiabetic drug that is a ligand for peroxisome proliferator activated receptor γ (PPARγ). Based on other studies that have implicated an immunosuppressive role for PPARγ during inflammatory responses, we hypothesized that troglitazone treatment would improve survival in a murine model of endotoxemia and that the protective effect would be mediated by decreased expression of inflammatory mediators. C57B1/6N x Sv/129 (wild-type [WT]) or PPARα null mice treated for 2 weeks with dietary troglitazone (0.1{\%}) had significantly fewer deaths and a higher LD50 value compared to control-fed mice when challenged with lipopolysaccharide (LPS). PPARα null mice were more sensitive to the lethal effects of LPS as evidenced by a 2-fold lower LD50 (6.6 mg/kg) compared to WT mice (14.6 mg/kg). Troglitazone treatment had no significant effect on LPS-induced plasma TNF, glucose, or nitric oxide levels in WT or PPARα null mice at any of the time points examined. However, troglitazone treatment significantly reduced LPS-induced plasma IL-6 levels in both WT and PPARα null mice. The results of these studies suggest that troglitazone treatment protects mice against a lethal challenge of LPS, but whether or not this effect is mediated through decreased expression of inflammatory mediators remains unclear.",
author = "Karen Reynolds and Bo Novosad and Adam Hoffhines and Jenny Gipson and Jared Johnson and Peters, {Jeffrey Maurice} and Frank Gonzalez and Jeffrey Gimble and Molly Hill",
year = "2002",
month = "1",
day = "1",
doi = "10.1179/096805102125000515",
language = "English (US)",
volume = "8",
pages = "307--314",
journal = "Innate Immunity",
issn = "1753-4259",
publisher = "SAGE Publications Ltd",
number = "4",

}

Reynolds, K, Novosad, B, Hoffhines, A, Gipson, J, Johnson, J, Peters, JM, Gonzalez, F, Gimble, J & Hill, M 2002, 'Pretreatment with troglitazone decreases lethality during endotoxemia in mice', Journal of Endotoxin Research, vol. 8, no. 4, pp. 307-314. https://doi.org/10.1179/096805102125000515

Pretreatment with troglitazone decreases lethality during endotoxemia in mice. / Reynolds, Karen; Novosad, Bo; Hoffhines, Adam; Gipson, Jenny; Johnson, Jared; Peters, Jeffrey Maurice; Gonzalez, Frank; Gimble, Jeffrey; Hill, Molly.

In: Journal of Endotoxin Research, Vol. 8, No. 4, 01.01.2002, p. 307-314.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pretreatment with troglitazone decreases lethality during endotoxemia in mice

AU - Reynolds, Karen

AU - Novosad, Bo

AU - Hoffhines, Adam

AU - Gipson, Jenny

AU - Johnson, Jared

AU - Peters, Jeffrey Maurice

AU - Gonzalez, Frank

AU - Gimble, Jeffrey

AU - Hill, Molly

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Troglitazone is an oral antidiabetic drug that is a ligand for peroxisome proliferator activated receptor γ (PPARγ). Based on other studies that have implicated an immunosuppressive role for PPARγ during inflammatory responses, we hypothesized that troglitazone treatment would improve survival in a murine model of endotoxemia and that the protective effect would be mediated by decreased expression of inflammatory mediators. C57B1/6N x Sv/129 (wild-type [WT]) or PPARα null mice treated for 2 weeks with dietary troglitazone (0.1%) had significantly fewer deaths and a higher LD50 value compared to control-fed mice when challenged with lipopolysaccharide (LPS). PPARα null mice were more sensitive to the lethal effects of LPS as evidenced by a 2-fold lower LD50 (6.6 mg/kg) compared to WT mice (14.6 mg/kg). Troglitazone treatment had no significant effect on LPS-induced plasma TNF, glucose, or nitric oxide levels in WT or PPARα null mice at any of the time points examined. However, troglitazone treatment significantly reduced LPS-induced plasma IL-6 levels in both WT and PPARα null mice. The results of these studies suggest that troglitazone treatment protects mice against a lethal challenge of LPS, but whether or not this effect is mediated through decreased expression of inflammatory mediators remains unclear.

AB - Troglitazone is an oral antidiabetic drug that is a ligand for peroxisome proliferator activated receptor γ (PPARγ). Based on other studies that have implicated an immunosuppressive role for PPARγ during inflammatory responses, we hypothesized that troglitazone treatment would improve survival in a murine model of endotoxemia and that the protective effect would be mediated by decreased expression of inflammatory mediators. C57B1/6N x Sv/129 (wild-type [WT]) or PPARα null mice treated for 2 weeks with dietary troglitazone (0.1%) had significantly fewer deaths and a higher LD50 value compared to control-fed mice when challenged with lipopolysaccharide (LPS). PPARα null mice were more sensitive to the lethal effects of LPS as evidenced by a 2-fold lower LD50 (6.6 mg/kg) compared to WT mice (14.6 mg/kg). Troglitazone treatment had no significant effect on LPS-induced plasma TNF, glucose, or nitric oxide levels in WT or PPARα null mice at any of the time points examined. However, troglitazone treatment significantly reduced LPS-induced plasma IL-6 levels in both WT and PPARα null mice. The results of these studies suggest that troglitazone treatment protects mice against a lethal challenge of LPS, but whether or not this effect is mediated through decreased expression of inflammatory mediators remains unclear.

UR - http://www.scopus.com/inward/record.url?scp=0036376343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036376343&partnerID=8YFLogxK

U2 - 10.1179/096805102125000515

DO - 10.1179/096805102125000515

M3 - Article

VL - 8

SP - 307

EP - 314

JO - Innate Immunity

JF - Innate Immunity

SN - 1753-4259

IS - 4

ER -